Clinical Trial Update: Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update reporting results for Cyclophosphamide, Alvocidib, and Rituximab in high-risk B-cell chronic lymphocytic leukemia or sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Alvocidib (Flavopiridol)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Status: TERMINATED